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Abstract 
Objective: Treating tic disorder is challenging. No trial has ever examined whether twice weekly aripiprazole is effec-
tive for treating tic disorders.
Methods: Participants of this 8-week randomized controlled parallel-group clinical trial were a clinical sample of 36 
children and adolescents with tic disorder. Yale global tic severity scale was used to assess the outcome. Both groups 
received daily dosage of aripiprazole for the first 14 days. Then, one group received daily dose of aripiprazole while the 
other group received twice weekly dosage of aripiprazole for the next 46 days. The patients were assessed at baseline, 
week 2, 4, and 8.
Results: Tic scores decreased in both group significantly 22.8 (18.5) versus 22.0 (11.6). Moreover, there was no 
between group difference. The final mean (SD) score of motor and vocal tics in the group treated with daily treat-
ment was not significantly different from the twice weekly group (Cohen’s d = 0.36). The odds ratios for sedation and 
increased appetite were 3.05 and 3, respectively.
Discussion: For the first time, current findings support that twice weekly aripiprazole efficacy was not different from 
that of daily treatment. The rate of drowsiness in the twice weekly treatment group was less than that of the daily 
treatment group.
This trial was registered at http://www.irct.ir. The registration number of this trial was: IRCT201312263930N32. http://
www.irct.ir/searchresult.php?id=3930&number=32
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Background
The neurodevelopmental disorder of Tourette’s syndrome 
is usually chronic with both motor and vocal tics. Its rate 
in boys is higher than that in girls [1]. Not only the com-
plexity of tic disorders but also their treatments and the 
effectiveness and adverse effects of the medications are 
major challenges for specialists [2, 3]. There is no medi-
cation to ameliorate all the symptoms of tic disorder in all 
patients. Behavior therapy reduces tic symptom severity 
in patients with tic disorders [4]. Habit reversal train-
ing is a type of behavior therapy. It markedly reduces tic 
severity [5]. Psycho-education is a major part of treat-
ment to increase the tolerance of the patients. Pharmaco-
therapy does not cure tic symptoms but it may control or 
decrease some symptoms.
While there is no consensus about treating tic disor-
ders with medications, pharmacotherapy usually includes 
dopamine antagonists such as typical and atypical antip-
sychotics (such as aripiprazole), and α-2-adrenoreceptor 
agonists (e.g., clonidine).
In addition to concerns about the efficacy, antipsy-
chotic related adverse effects such as extrapyramidal 
symptoms, increased prolactin, sedation and increased 
weight are among the concerns for pharmacotherapy.
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Aripiprazole has been introduced for treating tic dis-
orders [2]. There is good evidence regarding its effective-
ness and safety in tic disorder [6]. A 10-week multicenter, 
double-blind, randomized, placebo-controlled trial on 61 
children and adolescents with the diagnosis of Tourette’s 
disorder showed that aripiprazole  in comparison to pla-
cebo was effective and relatively safe in the short-term 
treatment [7]. Aripiprazole decreased 15 score from the 
score of YGTS scale [7]. Other uncontrolled and con-
trolled studies also support these findings in children and 
adolescents [8–10].
Aripiprazole [3.22 (1.9) mg/day] is as effective as risp-
eridone [0.6 (0.2) mg/day] for treating tic disorders [11]. 
Moreover, the safety of these two medications is compa-
rable in children and adolescents with tic disorders [11].
The oral availability of aripiprazole is 87  % [12]. The 
plasma concentrations of  aripiprazole  and its active 
metabolite both reach a steady state by Day 14 after 
repeated oral administration [13]. Its mean elimina-
tion half-life ranges from 47 to 68 h [14]. Another study 
reported that its mean elimination half-life was about 75 h 
while the half-life of its active metabolite was 94 h [12].
Because of the long half-life of aripiprazole, it is admin-
istered daily although it might be administered twice-
weekly. Adverse effects are major concern for treating tic 
disorders with medications. Many of these adverse effects 
are dose dependent. For example, sedation and increased 
appetite are common. Both of these adverse effects nega-
tively impact educational and social functioning of stu-
dents. Sometimes, these adverse effects might decrease 
treatment adherence. We could not find any trial exam-
ined whether twice-weekly administration of aripiprazole 
is effective and safe as much as its daily administration.
It is hypothesized that twice-weekly aripiprazole as 
much as daily aripiprazole is effective for treating tic 
disorders.
Methods
Participants of this 8-week randomized controlled paral-
lel-group clinical trial were a clinical sample of 46 chil-
dren and adolescents with tic disorder aged less than 
19  years old. The diagnoses of tic disorders were made 
using DSM-IV diagnostic criteria by a board certified 
child and adolescent psychiatrist. The severity of tic dis-
order was measured using a semi-structured clinical 
interview, the Yale global tic severity scale (YGTSS) [15].
Adverse effects were checked using a checklist based on 
the most common adverse effects of aripiprazole. Patient 
or parent-reported adverse effects were also recorded 
[11]. Concomitant medications were documented.
Patients were randomly allocated into one of the two 
groups. Random numbers were provided by a random 
number generator. Both groups received aripiprazole 
(starting dose of 1.25 mg/day and is titrated up to 7.5 mg/
day during 1 week) [16]. Both groups received daily dos-
age of aripiprazole for the first 14 days. Then, one group 
received daily dose of aripiprazole while the other group 
received twice weekly dosage of aripiprazole for the next 
46  days. Dosage could be adjusted according to side 
effects. Psychotropic drugs to control comorbid psychi-
atric symptoms were allowed during the trial. Assess-
ments were occurred at pre-intervention, week 2, 4, and 
8. Medication adherence was checked through asking the 
patients and the parents.
The exclusion criteria were current mood disorders, 
psychotic symptoms, severe uncontrolled general medi-
cal conditions or neurological problems and such as dia-
betes, epilepsy, Huntington’s chorea, reported cardiac 
problems, and clinically estimated mental retardation. 
Patients were drug free in the last 2  weeks prior entry 
into this trial. Otherwise, there was no significant dosage 
change in the last 2 weeks or during the trial.
Subjects were both males and females, aged 6–18 years 
old. YGTSS score more than 21 on YGTSS was required 
to enter this trial or tics had to be severe producing 
marked parent-or subject-reported distress or impair-
ment [11]. This score is considered as a moderate severity 
[16].
Ethics Committee of Shiraz University of Medical Sci-
ences approved this trial (no. 6631). The assent and writ-
ten informed consent were provided by the children and 
their parents, respectively.
The total tic subscale of Yale global tic severity scale 
score was our main outcome measurement [15]. It con-
sists of the total score of both vocal and motor tic severity 
ranging from 0 to 50. Total Yale global tic severity scale 
score consists of Total tic severity score plus the score of 
impairment related to the vocal and motor tics. Its score 
ranges from 0 to 100.
Similar to our previous trial [11], at least 35 % decline 
considered as a treatment response. However, complete 
response was defined as more than 50  % decline in tic 
symptoms as measured on the YGTSS.
A previous clinical trial showed that the daily admin-
istration of aripiprazole decreased total tic severity score 
from 16.5 (6.4) to 5.7 (6.2) during 2 months [11]. Another 
trial showed that aripiprazole declined 15 score from 
YGTSS [7]. Therefore, a total of 20 patients (10 patients 
in each group) is required to be entered in this two-treat-
ment parallel-design trial based on the assumption of the 
true difference between treatments 9.0 units, standard 
deviation = 6, P = 0.05, and power = 85 %.
Data analysis
SPSS for Windows was used to run the statistical analy-
sis. Sample Kolmogorov–Smirnov Test was performed 
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to test normal distribution (P = 0.97). Gender ratio and 
response rates were compared between the two groups 
using Fisher’s exact test or Chi-Square test, whenever it 
was applicable. t test was used to compare the mean of 
age and the decline of YGTSS between the two groups. 
Repeated measure analysis of variance (ANOVA) was 
performed to evaluate the overall efficacy rate. Cohen’s 
d was used to assess effect size. Relative risk ratio was 
used to compare the effect size the two treatments for 
complete remission. Intention-to-treat analysis  (ITT) 
with  last-observation-carried-forward  (LOCF) for the 
patients who had been assessed for at least 2 sessions was 
performed to handle the missing data.
P value less than 0.05 was set as the statistically signifi-
cant difference.
Results
The characteristics of the patients are displayed in 
Table  1. Gender ratio and mean age were not different 
between the two groups. The rates of co-morbid psychia-
try disorders were not different between the two groups 
(Table 1). The frequency of concurrent medications was 
not different between the two groups too (Table 1). Out 
of 46 patients were screened for entering this trial, ten 
patients were excluded due to inclusion or exclusion 
criteria. The reasons for the exclusions are presented in 
the CONSORT flow diagram (Fig. 1). One patient in the 
daily treatment group and one patient in the twice weekly 
group withdrew their consent for participation.
Four patients in the twice weekly group dropped out at 
week 4. The reasons for the dropout were: being ineffec-
tive (n = 2), and markedly improved (n = 2).
Three patients in the daily treatment group did not 
complete this trial. All of them dropped out at week 4. 
One of them dropped out because the patients markedly 
improved. The other one dropped out with an unknown 
reason. The reason for another patient was hospitaliza-
tion due to pneumonia.
Total Yale global tic severity scale score (motor tics + vocal 
tics + impairments)
The mean of Total Yale global tic severity scale score at 
baseline in the daily treatment group and twice weekly 
treatment group was 89.6 (39.2) and 93.8 (29.3), respec-
tively (t = 0.3, df = 34, P = 0.72) (Table 1).
The results of Repeated-measure ANOVA showed 
significant effect for time during this trial (Sphericity 
Assumed: F3, 93 = 56.8, P < 0.001) (Fig. 2). The interac-
tion of time ×  treatment was not statistically significant 
(Sphericity Assumed: F3, 93 = 0.74, P = 0.4). There was 
no between group difference (F1, 31 = 0.85, P = 0.36). At 
the end of this trial, the mean decline of TYGTSS in the 
daily treatment group and twice weekly treatment group 
was not different between the two groups [76 (37.9) ver-
sus 64.6 (44.2), respectively, t  =  0.8, df  =  32, P  =  0.4] 
(Table 1).
By week 8, the rate of partial response was 100.0 % in 
the daily treatment group. The rate in the twice weekly 
treatment group was 73.3  % (P  <  0.02). However, the 
rate of complete response (more than 50  % decline in 
TYGTSS was not different between the two groups. The 
rate in the daily treatment group was 89.5 % while it was 
73.3  % in the twice weekly group. These rates were not 
different between the two groups (P = 0.3). The response 
rates yield a relative risk ratio of 1.22.
Total Yale tic severity scale score (motor tics + vocal tics)
The mean score of TYTSS was not different between the 
two groups at baseline (Table 1). TYTSS decreased 27.8 
(18.5) and 22.0 (11.6) in the daily treatment group and 
twice weekly treatment group, respectively.
Repeated-measure ANOVA displayed that there was 
a significant effect for time during this trial (Spheric-
ity Assumed: F3, 93  =  48.7, P  <  0.001). Moreover, the 
interaction of time × treatment was not statistically sig-
nificant (Sphericity Assumed: F3, 93  =  0.43, P  =  0.43) 
(Table 1). In addition, there was no significant difference 
between the two groups (F1, 31 = 0.01, P = 0.92).
By week 8, while the rate of partial response was dif-
ferent between the two groups, the rate of complete 
response (more than 50 % decline in TYTSS) was not dif-
ferent between the two groups (P = 0.3).
The final mean (SD) score in the group treated with 
daily treatment was not significantly different from the 
twice weekly group [6.6 (5.9) versus 9.7 (1.2); P = 0.3], a 
difference of −3.1 and Cohen’s d = 0.36 [6.6–9.7 = −3.1; 
3.1/8.5 (pooled SD) = 8.5].
Vocal tics
There was no between group difference regarding the 
effect on the vocal tice (F1, 30 = 0.11, P = 0.7) (Fig. 3). 
The interaction of time × treatment was not statistically 
significant (F3, 90 = 0.32, P = 0.68).
Motor tics
As it is displayed in the Fig.  4, the effect of groups on 
the motor tics score was not different (F1, 31  =  0.02, 
P = 0.8). The interaction of time × treatment was statisti-
cally non-significant (F3, 33 = 1.43, P = 0.24).
Adverse effect
The most common adverse effect was drowsiness. The 
rate of drowsiness in the daily treatment group and twice 
weekly group was 52.6 and 26.7 %, respectively (Table 2). 
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The odds ratio for sedation was 3.05 (95  % Confidence 
Interval: from 0.71 to 13.10). The odds ratio for increase 
appetite was 3 (95  % Confidence Interval: from 0.50 to 
17.70). The other most common adverse effects in the 
daily treatment group were increased appetite (31.6  %), 
fatigues (10.5  %), irritability (10.5  %), and headache 
(10.5 %). The most common adverse effects in the twice 
weekly group were drowsiness (26.7 %), increased appe-
tite (10.3), fatigue (10.3), and nausea (10.3).
Discussion
Current results of this randomized, open label, control 
clinical trial suggest that twice weekly administration 
of aripiprazole is as effective as daily administration of 
Table 1 Characteristics of the patients in the daily treatment group and twice weekly treatment group
Daily treatment  
group
Twice weekly  
treatment group
Significance
Mean (SD) years of age 10.5 (3.1) 10.8 (2.0) t = .3, df = 34, P = 0.72
Gender
Boys 16 (80 %) 14 (87.5 %) P = 0.67
Girls 4 (20 %) 2 (12.5 %)
Comorbid psychiatric disorder
ADHD 6 (37.5 %) 5 (41.7 %) X2 = 0.05, df = 1, P = 0.8
Oppositional defiant disorder 7 (43.8 %) 7 (58.3 %) X2 = 0.5, df = 1, P = 0.4
Separation anxiety disorder 0 2 (16.7 %) –
Obsessive compulsive disorder 1 (6.2 %) 0 –
Con-current medications (n)
Carbamazepine 1 – –
Ritalin (10 mg/day) 1 – –
Imipramine (10 mg/day) + haloperidole (0.5 mg/day) – 1 –
Mean dosage of aripiprazole
First 2 weeks 3.5 3.8 –
Second 2 weeks 3.8 4.6 –
Second month 4.0 4.5 –
Motor and vocal tics score
Baseline 33.6 (18.2) 31.3 (7.6) t = .4, df = 34, P = 0.6
Week 2 15.1 (10.8) 12.8 (9.1) t = 0.6, df = 32, P = 0.52
Week 4 11.0 (9.7) 12.8 (10.9) t = 0.5, df = 31, P = 0.6
Week 8 6.6 (5.9) 9.7 (11.2) t = 1.03, df = 32, P = 0.3
Mean (SD) decline of total Yale motor and vocal tic severity  
scale score during trial
22.8 (18.5) 22.0 (11.6) t = 1.07, df = 32, P = 0.2
Response rate with more than 35 % decline in total Yale motor and 
vocal tic severity scale score
19 (100.0 %) 11 (73.3 %) P < 0.02
Response rate with more than 50 % decline in total Yale motor and 
vocal tic severity scale score
17 (89.5 %) 11 (73.3 %) P = 0.2
Total Yale global tic severity scale score (motor tics + vocal tics + impairments)
Baseline 89.6 (39.2) 93.8 (29.3) t = 0.3, df = 34, P = 0.72
Week 2 39.5 (33.33) 37.8 (31.3) t = 0.1, df = 32, P = 0.8
Week 4 27.1 (31.9) 39.2 (36.7) t = 1.0, df = 31, P = 0.31
Week 8 15.3 (17.2) 29.7 (37.1) t = 1.4, df = 32, P = 0.14
Mean (SD) decline of total Yale global tic severity scale score during 
trial (motor tics + vocal tics + impairments)
76 (37.9) 64.6 (44.2) t = 0.8, df = 32, P = 0.4
Response rate with more than 35 % decline in total Yale global tic 
severity scale score (motor tics + vocal tics + impairments)
19 (100.0 %) 11 (73.3 %) P < 0.02
Response rate with more than 50 % decline in total Yale global tic 
severity scale score (motor tics + vocal tics + impairments)
17 (89.5 %) 11 (73.3 %) P = 0.3
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aripiprazole in the reduction of tics in children and ado-
lescents with Tourette’s disorder. Both treatment proto-
cols significantly decreased the tics score. In addition, the 
rate of complete response was not different between the 
two groups. However, one group received aripiprazole 
every day while the other group received it twice weekly 
(every Saturdays and Tuesdays). The relative risk ratio 
of 1.22 shows that the probability of response to daily 
treatment is not markedly higher than that of the twice-
weekly treatment.
These results support our hypothesis that twice weekly 
administration of aripiprazole is effective for treating 
Tourette’s disorder. This is in similar line with long half-
life of aripiprazole and its metabolite. For the first time, 
current findings support that twice weekly aripiprazole 





Not meeting inclusion criteria (n=6) 
No consent (n=2) 
Age more than 19 (n=1) 
Taking methylphenidate (n=1) 
Allocated to daily treatment group 
(n=20) 
Received allocated intervention (n=19)
Twice weekly group (n=16) 
 Received allocated intervention (n=15) 





Week 4(n=19) Week 4(n=15) 
Week 8 (n=16) 
Week 8(n=11) 
Declined to participate 
(n=1) 
Did not answered our calls 
(n=1) 
Declined to participate 
(n=1) 
Did not answered our 
calls (n=1) 
Lost to follow-up (n=3) 
Markedly improved 
(n=1) 
Hospitalization due to 
pneumonia (n=1) 





Fig. 1 The CONSORT flow diagram of the patients in this trial
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Patients in both groups tolerated the medication very 
well. The rate of adverse effects was similar between 
the two groups. The adverse effects were not severe and 
they were manageable well. No one dropped out due to 
adverse effects. The most common adverse effect was 
drowsiness. The rate of drowsiness in the twice weekly 
treatment group was half of the daily treatment group. 
The odds ratio of 3 for drowsiness and increased appetite 
indicates that the patients in the daily treatment group 
suffer from sedation and increased appetite more than 
three times from the control group. Current literature 
support that aripiprazole is commonly well tolerated 
[17] and it is considerably safe in children and adolescent 
[18]. Its adverse effects are mild to moderate and tran-
sient [17]. If further well controlled double blind con-
trolled clinical trial support current finding, twice weekly 
administrating of aripiprazole is preferred in compare to 
daily administrating.
There are some limitations needed to be taken into 
account. This short term, small sample size, and open 
label trial was from a specialty clinic. It may reduce the 
generalizability of the results. In addition, the rater and 
the patients were not blinded to treatment group. Fur-
ther trials should examine blood data including verify-
ing the patients’ reports and indicating a profile how the 
drugs serum’s level develop and the degree of fluctuation 
despite the long half-life to a certain degree.
Despite these limitations, this is the first randomized 
controlled clinical trial examining the effectiveness and 
safety of twice weekly treatment of Tourette’s disorder 
with aripiprazole.
Current results encourage performing further large 
sample size, double blind randomized control clinical 
trials.
Fig. 2 Changes of the sum up of motor and vocal tics score during 
this trial by the groups
Fig. 3 Changes of the vocal tics score during this trial by the groups
Fig. 4 Changes of the motor tics score during this trial by the groups
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Conclusion
According to the current results, the efficacy of daily 
treatment with aripiprazole was not different from the 
twice weekly treatment for treating Tourette’s disorder in 
children and adolescents.
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